Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
To evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with camrelizumab (hereafter, TACE-camrelizumab) in the treatment of patients with recurrent hepatocellular carcinoma (R-HCC) after curative resection.